Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Leases (2022 - 2025)

Historic Operating Leases for Fulcrum Therapeutics (FULC) over the last 4 years, with Q3 2025 value amounting to $4.7 million.

  • Fulcrum Therapeutics' Operating Leases fell 3349.02% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 3349.02%. This contributed to the annual value of $6.4 million for FY2024, which is 2533.32% down from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Operating Leases stood at $4.7 million, which was down 3349.02% from $5.3 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Operating Leases registered a high of $12.8 million during Q1 2022, and its lowest value of $4.7 million during Q3 2025.
  • Over the past 4 years, Fulcrum Therapeutics' median Operating Leases value was $8.6 million (recorded in 2023), while the average stood at $8.7 million.
  • In the last 5 years, Fulcrum Therapeutics' Operating Leases tumbled by 2004.54% in 2024 and then plummeted by 3349.02% in 2025.
  • Over the past 4 years, Fulcrum Therapeutics' Operating Leases (Quarter) stood at $10.8 million in 2022, then decreased by 20.26% to $8.6 million in 2023, then fell by 25.33% to $6.4 million in 2024, then dropped by 27.63% to $4.7 million in 2025.
  • Its Operating Leases was $4.7 million in Q3 2025, compared to $5.3 million in Q2 2025 and $5.9 million in Q1 2025.